Evidence map›Paper›PMID 41606245›Full record

ArticleEuropean radiology2026

A comprehensive multi-task deep learning model for kidney cancer: histological subtyping, clinical staging, and anatomical complexity grading.

Dongqin Lv, Renyi Liu, Xiaochun Wang, Tianli Liang, Ling Zhang, Weixiong Zeng, Zilong He, Limei Deng, Zhi Zhang, Genggeng Qin and 1 more

Abstract readMulticenter Study
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dongqin Lv *Department of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Renyi Liu *Department of Radiology, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China.
Xiaochun Wang *Medical Imaging Center, Ganzhou People's Hospital, Ganzhou, China.
Tianli LiangDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Ling ZhangDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Weixiong ZengDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Zilong HeDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Limei DengDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Zhi ZhangDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China.
Genggeng QinDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China. zealotq@smu.edu.cn.
Weiguo ChenDepartment of Radiology, NanFang Hospital, Southern Medical University, Guangzhou, China. chen1999@smu.edu.cn.ORCID http://orcid.org/0000-0003-1552-0511

Funding

National Natural Science Foundation of China 82171929
6 · The paper itself

Abstract

objectivesTo develop and validate a multi-task deep learning (MTDL) model using multiphase contrast-enhanced CT (CECT) for simultaneously assessing histological subtypes, clinical stages, and anatomical complexity grades of solid malignant renal tumors. MATERIALS AND

methodsThis two-center retrospective study included patients with solid malignant renal tumors and their preoperative kidney CECT images. A progressive layered extraction (PLE)-based MTDL model was trained and externally tested. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA), compared with the results of five radiologists.

resultsAmong 798 patients (mean age, 54 ± 12 years; 279 females; Center A: n = 620, Center B: n = 178), 597 (74.8%) had clear cell renal cell carcinomas (ccRCC), 150 (18.8%) were clinical staging III/IV, and 187 (23.4%) had high anatomical complexity. On the external test set, the MTDL model achieved AUCs of 0.89 (95% CI: 0.82, 0.94) for distinguishing ccRCC from non-ccRCC, 0.87 (95% CI: 0.81, 0.93) for clinical staging (I/II vs. III/IV), and 0.87 (95% CI: 0.82, 0.92) for anatomical complexity grading (low-intermediate vs. high). The MTDL model outperformed single-task deep learning (STDL) in clinical staging (AUC: 0.87 vs. 0.82, p = 0.022), showed higher net benefit on DCA, and demonstrated better diagnostic performance than junior radiologists in histological subtyping and clinical staging. Additionally, it used 68% less memory and was 60% faster than STDL models.

conclusionThe CECT-based MTDL model demonstrated robust performance in simultaneously predicting histological subtypes, clinical stages, and anatomical complexity grades of malignant renal tumors. KEY POINTS: Question Accurate preoperative description of the histological subtyping, clinical staging, and anatomical complexity of malignant renal tumors is crucial for treatment decision-making. Findings By sharing features, the multi-task deep learning algorithm model enhances clinical staging performance and significantly improves computational efficiency in predicting all three tasks simultaneously. Clinical relevance The multi-task deep learning algorithm model enables rapid and accurate comprehensive preoperative evaluation of renal tumors, which assists surgeons in optimizing surgical plans and promotes the advancement of renal tumor management toward precision and efficiency.

Indexed as

Carcinoma, Renal CellDeep LearningKidney NeoplasmsTomography, X-Ray ComputedAdultAgedContrast MediaFemaleHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingRetrospective StudiesContrast MediaArtificial intelligenceDeep learningKidney neoplasmsTomography, X-ray computed

Identifiers

PMID41606245
PMCPMC13212381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.